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OBJECTIVES The goal of this study was to define the prognostic value of serum myoglobin in patients with
non–ST-elevation acute coronary syndromes (ACS).
BACKGROUND While myoglobin is useful for the early diagnosis of myocardial infarction (MI), its role in the
early risk-stratification of patients with ACS has not been established.
METHODS Myoglobin, creatine kinase-MB subfraction (CK-MB) and troponin I (cTnI) were measured
at randomization in 616 patients from the Thrombolysis In Myocardial Ischemia/Infarction
(TIMI) 11B study and 1,841 patients from the Treat Angina with Aggrastat and Determine
Cost of Therapy with an Invasive or Conservative Therapy-Thrombolysis In Myocardial
Ischemia/Infarction (TACTICS-TIMI) 18 study. The risks for death and nonfatal MI
through six months of follow-up were compared between patients with and without
myoglobin elevation (110 g/l) in each study and in a dataset combining all eligible patients
from both studies (n  2,457).
RESULTS In a multivariate model adjusting for baseline characteristics, ST changes and CK-MB and
cTnI levels, an elevated baseline myoglobin was associated with increased six-month mortality
in TIMI 11B (adjusted odds ratio [OR] 2.9 [95% confidence interval {CI} 1.2 to 7.1]),
TACTICS-TIMI 18 (adjusted OR 3.0 [95% CI 1.5 to 5.9]) and the combined dataset
(adjusted OR 3.0 [95% CI 1.8 to 5.0]). In contrast, there was no significant association
between myoglobin elevation and nonfatal MI (combined dataset adjusted OR 1.55, 95% CI
0.9 to 2.6). In TACTICS-TIMI 18, patients with versus those without myoglobin elevation
were more likely to have an occluded culprit artery (28% vs. 10%; p  0.0001) and visible
thrombus (49% vs. 34%; p  0.006) and less likely to have TIMI 3 flow (53% vs. 68%; p 
0.009).
CONCLUSIONS A serum concentration of myoglobin above the MI detection threshold (110 g/l) is
associated with an increased risk of six-month mortality, independent of baseline clinical
characteristics, electrocardiographic changes and elevation in CK-MB and cTnI. These
findings suggest that myoglobin may be a useful addition to cardiac biomarker panels for early
risk-stratification in ACS. (J Am Coll Cardiol 2002;40:238–44) © 2002 by the American
College of Cardiology Foundation
Myoglobin is a small (17.8 kd), cytosolic protein that is
among the earliest markers released into the circulation after
the onset of myocardial necrosis (1). Because myoglobin is
also present in adult skeletal muscle, elevation in serum
myoglobin is not specific for cardiac injury. Indeed, as assays
for highly specific cardiac biomarkers such as troponin I
(cTnI) and T (cTnT) have become widely available, the
value of myoglobin has come under question (2), and
current guidelines recommend myoglobin measurement
only for patients presenting within 6 h of chest pain onset
(3).
Recent studies have demonstrated that, among patients
with ST-elevation myocardial infarction (MI), those with
myoglobin elevation before the initiation of fibrinolytic
therapy are at high risk for death and heart failure (4). In
this setting, the prognostic value of myoglobin is indepen-
dent of baseline variables, time to initiation of reperfusion
therapy, infarct location and measures of the efficacy of
therapy such as ST-segment resolution (4). A later mea-
surement of myoglobin, obtained 12 h after the administra-
tion therapy, was also shown to discriminate patients at high
and low risk for mortality. For this purpose, myoglobin
From the *Thrombolysis In Myocardial Infarction (TIMI) Study Group, †Donald
W. Reynolds Cardiovascular Clinical Research Center, University of Texas South-
western Medical School, Dallas, Texas; ‡Cardiovascular Division, Brigham and
Women’s Hospital, §Harvard Clinical Research Institute, Boston, Massachusetts;
and the Children’s Hospital, Boston, Massachusetts. Supported by grants from
Aventis Pharmaceuticals (TIMI 11B) and Merck and Co. (TACTICS-TIMI 18).
Assay reagents were provided by Bayer Diagnostics, Inc.
Manuscript received December 17, 2001; revised manuscript received March 7,
2002, accepted April 18, 2002.
Journal of the American College of Cardiology Vol. 40, No. 2, 2002
© 2002 by the American College of Cardiology Foundation ISSN 0735-1097/02/$22.00
Published by Elsevier Science Inc. PII S0735-1097(02)01948-4
performed better than cTnI and creatine kinase-MB sub-
fraction (CK-MB) (5).
For patients presenting to the emergency room with chest
pain in the absence of ST-elevation, the addition of myo-
globin to biomarker panels that include CK-MB and cTnI
or cTnT improves sensitivity for the detection of MI,
particularly in patients presenting early after symptom onset
(2,6–11). Beyond the diagnosis of MI, it is important to
consider whether myoglobin is useful for risk stratification
in patients with non–ST-elevation acute coronary syn-
dromes (ACS). Here, data are more limited: while one
recent study has suggested that myoglobin provides incre-
mental prognostic information to CK-MB and troponin
(12), others have not reached the same conclusion
(8,9,13,14). We performed the present analyses to evaluate
the role of myoglobin for risk stratification in patients with
non–ST-elevation ACS and to determine whether therapy
with enoxaparin, or with an early invasive management
strategy, might be of particular benefit in patients with
myoglobin elevation.
METHODS
Patient populations. The present study was conducted in
two distinct patient populations. The hypotheses were
initially tested in a substudy of the Thrombolysis In Myo-
cardial Ischemia/Infarction (TIMI) 11B trial and then
prospectively validated in the Treat Angina with Aggrastat
and Determine Cost of Therapy with an Invasive or
Conservative Therapy-Thrombolysis In Myocardial Isch-
emia/Infarction (TACTICS-TIMI) 18 trial. The TIMI
11B was a randomized double-blind trial comparing unfrac-
tionated heparin with the low molecular weight heparin
enoxaparin in 3,910 patients with suspected non–ST-
elevation ACS, conducted between 1996 to 1998 (15).
TACTICS-TIMI 18 was a randomized trial comparing
early invasive and early conservative management strategies
in 2,220 patients with non–ST-elevation ACS treated with
the glycoprotein IIb/IIIa receptor inhibitor tirofiban, un-
fractionated heparin and aspirin conducted between 1997 to
2000 (16). Both trials required that patients present with
evidence of ischemic discomfort at rest and either dynamic
electrocardiographic (ECG) changes, elevated cardiac
markers or documented prior evidence of coronary artery
disease. Patients in both trials provided written informed
consent for participation (15,16).
Of 681 patients in the TIMI 11B trial and 1,851 patients
in the TACTICS-TIMI 18 trial who provided baseline
blood samples, specimens were suitable for myoglobin
analysis in 616 and 1,841 patients, respectively. In both
trials, serum was separated and immediately frozen at
20°C or colder at the study site; samples were subse-
quently shipped on dry ice to the TIMI Biomarker Core
Laboratory at the Children’s Hospital in Boston, Massa-
chusetts, where they were stored at 80°C until assays were
performed.
Biochemical assays. All assays were performed on thawed
sera using the ACS:180 automated chemiluminescence
system (Bayer Diagnostics, Tarrytown, New York). Each of
the assays (myoglobin, cTnI and CK-MB) are two-site
sandwich immunoassays that use direct chemiluminescence
technology. For myoglobin, the manufacturer’s recom-
mended detection limit for MI is 110 g/l, and this
threshold was prospectively selected for the current studies.
Previous studies using this cTnI assay have established a
threshold of 0.1 g/l for assessing prognosis in patients with
non–ST-elevation ACS (17,18). The MI detection limit for
CK-MB with the ACS:180 assay is 5 g/l. Thus, a cTnI
threshold of 0.1 g/l and a CK-MB threshold of 5 g/l
were prospectively selected.
Clinical end points. The primary end point of the TIMI
11B trial was the composite of death, MI or severe ischemia
requiring urgent revascularization eight days after random-
ization. End points were also collected at 43 days and six
months (15). The primary end point of the TACTICS-
TIMI 18 trial was the composite of death, MI or rehospi-
talization for ACS at six months (16). All primary end point
events in both trials were adjudicated by clinical event
committees. Because both trials reported end points at six
months, the present analyses were based on six-month event
rates. While new or recurrent MI was defined using the
same criteria in both trials, recurrent ischemia was defined
differently; thus, the present analyses focus on the end
points of death and nonfatal MI at six months.
Statistical analyses. Analyses were performed in the TIMI
11B study population, the TACTICS-TIMI 18 study
population and a combined dataset including all patients
from both trials. Baseline variables were compared between
patients with and without myoglobin elevation using the
chi-square test for categorical variables and Student t test for
continuous variables. The relation between myoglobin and
six-month outcomes was evaluated considering myoglobin
both as a continuous and a categorical variable. First, the
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concentration of myoglobin was compared between patients
with and without adverse outcomes using the Wilcoxon
rank-sum test. Next, unadjusted associations between myo-
globin elevation and outcomes were assessed by calculating
relative risks with 95% confidence intervals (CI). Stratified
analyses were performed based on gender, index diagnosis
(unstable angina vs. non–ST-elevation MI), cTnI level
(0.1 vs. 0.1 g/l), CK-MB level (5 vs. 5 g/l), time
to randomization (0 to 6 h, 6 to 12 h and 12 h; TIMI
11B only) and treatment assignment (enoxaparin vs. unfrac-
tionated heparin in TIMI 11B, early invasive vs. early
conservative strategy in TACTICS-TIMI 18). Tests for
interaction with treatment assignment were performed.
Logistic regression modeling was performed for the end
point of six-month mortality. The following variables were
included: age, gender, diabetes, hypertension, prior aspirin
use, current smoking, index diagnosis, ST-deviation
1 mm, CK-MB 5 g/l, cTnI 0.1 g/l and myoglobin
110 g/l.
RESULTS
Baseline characteristics were similar between patients par-
ticipating in the TIMI 11B and TACTICS-TIMI 18
substudies (Table 1). The percentage of patients with
myoglobin elevation (110 g/l) at the time of random-
ization was 22% in TIMI 11B, 18% in TACTICS-TIMI
18 and 19% in the combined data set (Table 1). Patients
with myoglobin elevation were older, disproportionately
male and more likely to present with suspected MI, ST
changes on the ECG and elevation of cTnI and CK-MB
(Table 1).
In a subset of 454 patients from the invasive arm of the
TACTICS-TIMI 18 study, coronary angiograms were
reviewed by the TIMI Angiographic Core Laboratory. The
extent of coronary artery disease was similar between pa-
tients with and without myoglobin elevation (Table 2). In
contrast, patients with myoglobin elevation were more likely
than those without myoglobin elevation to have an occluded
culprit artery (28% vs. 10%; p  0.0001) and visible
thrombus (49% vs. 34%; p  0.006), and less likely to have
TIMI flow grade 3 in the culprit artery (53% vs. 68%; p 
0.009) (Table 2). When the angiographic analyses were
restricted to 312 patients with a cTnI0.1 g/l, myoglobin
elevation remained associated with a higher probability of
culprit artery occlusion (p  0.0001) and visible thrombus
(p  0.02).
Univariate associations with outcomes. The median
baseline concentration of myoglobin was significantly
higher among patients who died by six months versus those
alive at six months in TIMI 11B (104 vs. 52 g/l; p 
0.0001), TACTICS-TIMI 18 (79 vs. 53 g/l; p  0.005)
and the combined dataset (91 vs. 52 g/l; p  0.0001)
(Table 3). In contrast, the association between myoglobin
and the risk for new or recurrent nonfatal MI through six
months was less robust. In TIMI 11B, there was no
difference in myoglobin concentration between patients
Table 1. Baseline Characteristics in Patients With and Without Elevated Myoglobin (110 g/l) at the Time of Randomization
Variables
TIMI 11B TACTICS-TIMI 18 Combined
MYO < 110 MYO > 110 MYO < 110 MYO > 110 MYO < 110 MYO > 110
n 482 134 1,509 332 1,991 466
Age, yrs 63  11 66  12* 61  11 65  11‡ 61  11 65  11‡
Male gender, % 64 72 64 75* 64 74‡
Time to randomization, h 14  8 14  8 NA NA NA NA
Prior ASA, % 86 90 69 59‡ 74 68†
Prior MI, % 32 29 39 41 37 38
Current smoker, % 28 25 32 26† 31 26†
Diabetes, % 20 30† 28 29 26 29
Hypertension, % 57 63 66 66 64 65
Index diagnosis UA, % 64 16‡ 73 21 70 19
ST  1 mm, % 34 53‡ 18 31‡ 22 37‡
CK-MB 5 g/l, % 26 66‡ 28 83‡ 27 78‡
cTnI 0.1 g/l, % 55 90‡ 54 86‡ 54 87‡
cTnI 0.4 g/l, % 43 80‡ 43 80‡ 43 80‡
*p  0.01; †p  0.05; ‡p  0.001.
ASA aspirin; CK-MB creatine kinase-MB subfraction; cTnI cardiac troponin I; MImyocardial infarction; MYOmyoglobin (g/l); UA unstable angina. Other
abbreviations as in Abbreviation box.
Table 2. Association Between Myoglobin Elevation and
Angiographic Findings in TACTICS-TIMI 18
Variables
MYO < 110 g/l
(n  356)
MYO > 110 g/l
(n  98)
p
Value
No. vessels with 70%
diameter stenosis
0.56
1 44% 38%
2 34% 39%
3 22% 23%
TIMI flow grade 0.0001
0/1 10% 28%
2 22% 19%
3 68% 53%
Thrombus 0.005
Present 34% 49%
Absent 66% 51%
MYO  myoglobin; TIMI  Thrombolysis In Myocardial Infarction. Other
abbreviations as in Abbreviation box.
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with and without an end point MI, and in TACTICS-
TIMI 18 myoglobin levels were only modestly higher
among patients with versus those without an end point MI
(Table 3).
The unadjusted risk for mortality at six months was
significantly higher among patients with a baseline myoglo-
bin 110 g/l versus those with a myoglobin level at or
below this threshold in TIMI 11B (relative risk [RR] 3.4,
95% CI 1.8 to 6.4), TACTICS-TIMI 18 (RR 3.1, 95% CI
1.8 to 5.2) and the combined dataset (RR 3.3, 95% CI 2.2
to 4.9).
Stratified analyses. A consistent association between myo-
globin elevation and increased six-month mortality was
observed among men and women; patients with unstable
angina and those with non–ST-elevation MI; patients with
CK-MB 5 g/l and 5 g/l; patients with a cTnI
0.1 g/l and 0.1 g/l (Fig. 1) and those presenting 0 to
6 h, 6 to 12 h and 12 h after the onset of ischemic
symptoms (Table 4). In addition, in the TIMI 11B trial,
there was no interaction between time to randomization,
myoglobin elevation and six-month mortality (p interaction
0.48). In TIMI 11B, myoglobin elevation was associated
with increased six-month mortality both among patients
randomized to enoxaparin and those randomized to unfrac-
tionated heparin; in TACTICS-TIMI 18, myoglobin ele-
vation was associated with increased mortality both among
patients randomized to an early invasive strategy and those
randomized to an early conservative strategy (Table 4).
There was no interaction between treatment assignment,
myoglobin elevation and six-month mortality (p interaction
0.47 in TIMI 11B and p interaction  0.79 in TACTICS-
TIMI 18).
Multivariate analyses. In logistic regression analyses ad-
justing for age, gender, diabetes, hypertension, prior aspirin
use, smoking status, index diagnosis, ST changes, and
CK-MB and cTnI elevation, myoglobin elevation (110g/l)
remained associated with six-month mortality (TIMI 11B
adjusted odds ratio [OR] 2.9 [95% CI 1.2 to 7.1],
TACTICS-TIMI 18 adjusted OR 3.0 [95% CI 1.5 to 5.9],
combined dataset adjusted OR 3.0 [95% CI 1.8 to 5.0]).
When myoglobin, CK-MB and cTnI were entered into the
model as continuous variables, myoglobin remained inde-
pendently associated with six-month mortality (p  0.007
in the combined dataset). When the end point of MI was
substituted for mortality as the outcome variable, there was
no independent association between myoglobin elevation
(110 g/l) and the occurrence of MI through six months
(combined dataset adjusted OR 1.55, 95% CI 0.9 to 2.6). In
contrast, a significant association between cTnI elevation
(0.1 g/l) and the rate of MI through six months was
observed (adjusted OR 2.1, 95% CI 1.2 to 3.8).
DISCUSSION
In two separate contemporary cohorts of patients with
non–ST-elevation ACS, a serum concentration of myoglo-
bin above the MI detection threshold (110 g/l) was
associated with an increased risk of six-month mortality,
independent of baseline clinical variables, ECG changes and
elevation in CK-MB and cTnI. In contrast, after adjust-
ment for the same baseline variables, myoglobin elevation
Table 3. Correlation Between the Median (25th, 75th
Percentiles) Baseline Concentration of Myoglobin (g/l) and
Six-Month Outcomes
Variables
TIMI 11B
(n  616)
TACTICS-TIMI 18
(n  1,841)
Combined Database
(n  2,457)
Dead 104 (51, 195) 79 (38, 166) 91 (44, 174)
Alive 52 (34, 92) 53 (37, 87) 52 (36, 87)
p value 0.0001 0.005 0.0001
MI 50 (37, 87) 66 (43, 136) 59 (40, 119)
No MI 53 (35, 99) 52 (36, 87) 53 (36, 89)
p value 0.80 0.008 0.01
MI  myocardial infarction. Other abbreviations as in Abbreviation box.
Figure 1. Comparison of myoglobin and troponin I for predicting death and nonfatal myocardial infarction (MI) in the combined TIMI 11B/TACTICS-
TIMI 18 dataset. Open bar  normal myoglobin (110 g/l); solid bar  elevated myoglobin (110 g/l). cTnI  cardiac troponin I. For acronym
definition, see Abbreviation box.
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was not significantly associated with the occurrence of
nonfatal MI. No interaction with treatment assignment was
detected; myoglobin elevation was associated with increased
mortality whether patients received enoxaparin or unfrac-
tionated heparin in TIMI 11B or whether they were treated
with an early invasive or early conservative strategy in
TACTICS-TIMI 18.
Comparison with prior studies. Previous studies have
demonstrated that measuring myoglobin in addition to
CKMB and troponin I or T improves the early detection of
MI (6–11), but results have been inconsistent with regard to
the prognostic implications of myoglobin elevation in pa-
tients with non–ST-elevation ACS. Several studies have
suggested that myoglobin adds little prognostic information
to CK-MB and troponins (8,9,13,14); however, these stud-
ies have been small and have included few mortality end
points. Because myoglobin appears to predict mortality to a
greater extent than it does MI, large sample sizes would be
required to provide sufficient statistical power to evaluate the
prognostic value of myoglobin independent of other risk
predictors. In the Chest Pain Evaluation by Creatine
Kinase-MB, Myoglobin and Troponin I (CHECKMATE)
study, which included 1,005 patients, a diagnostic strategy
that included myoglobin, CK-MB and cTnI measurement
identified more patients at risk for death by 30 days than did
a strategy employing only CK-MB and cTnI. In contrast,
the addition of myoglobin to CK-MB and cTnI did not
improve the prediction of recurrent MI (12).
Clinical implications. Our findings in 2,457 patients with
non–ST-elevation ACS are consistent with the results of
the CHECKMATE study. Taken together, these studies
suggest that different cardiac biomarkers may have greater
relative predictive value for different cardiovascular end
points. For example, the cardiac troponins appear to provide
excellent discrimination of the risk for recurrent ischemic
events (MI and recurrent ischemia) but may not provide
comparable mortality prediction to myoglobin, particularly
when one considers low-level troponin elevation, that is, in
the 0.1 to 1.5 g/l range (Fig. 1). The relative specificity of
low-level troponin elevation for nonfatal end points may
help to explain why troponin elevation identifies patients
likely to benefit from potent antiplatelet and antithrombotic
agents and an early invasive treatment strategy (16,18–20).
These therapies appear to reduce nonfatal ischemia events
to a greater extent than mortality (15,16,21). In contrast
with cTnI, myoglobin appears to be more predictive of
mortality than of nonfatal ischemic end points. Studies are
needed in which specific therapies are targeted to patients
with myoglobin elevation in an attempt to reduce mortality.
Biologic rationale. Both principal observations of this
study, first, that myoglobin is associated with mortality
independent of cTnI and CK-MB and, second, that it is not
associated with the risk for nonfatal MI, are somewhat
surprising because myoglobin, CK-MB and cTnI have all
been classified together as markers of tissue necrosis. In-
deed, the present findings raise the possibility that release of
Table 4. Unadjusted Relative Risk (95% CI) for 6-Month Mortality in Patients With Elevated
Baseline Myoglobin (110 g/l)
TIMI 11B
(n  616)
TACTICS-TIMI 18
(n  1,841)
Combined Dataset
(n  2,457)
All patients 3.4 (1.8–6.4) 3.1 (1.8–5.2) 3.3 (2.2–4.9)
Gender
Men 2.4 (1.0–5.5) 2.8 (1.4–5.3) 2.7 (1.6–4.5)
Women 6.1 (2.2–16.7) 4.1 (1.7–9.5) 5.0 (2.7–9.5)
Index diagnosis*
Unstable angina 5.2 (2.1–13.1) 1.9 (0.6–6.2) 3.2 (1.5–6.6)
Non–Q-wave MI 5.4 (1.4–18.8) 3.5 (1.6–7.6) 4.0 (2.1–7.7)
Cardiac biomarkers
CK-MB  5 g/l 3.2 (1.3–7.7) 2.2 (0.7–7.1) 3.1 (1.6–6.2)
CK-MB  5 g/l 5.1 (1.5–17.7) 3.6 (1.6–8.1) 4.1 (2.1–8.0)
cTnI  0.1 g/l 3.1 (0.4–24.7) 2.9 (0.7–13.1) 3.0 (0.9–10.0)
cTnI  0.1 g/l 2.7 (1.4–5.5) 2.5 (1.4–4.4) 2.7 (1.7–4.2)
cTnI  1.5 g/l 2.7 (1.0–7.3) 2.4 (1.1–5.1) 2.6 (1.4–4.6)
cTnI  1.5 g/l 4.3 (1.8–10.3) 4.1 (1.9–9.0) 4.4 (2.5–7.9)
Time from chest pain onset to randomization
0–6 h 4.2 (1.2–14.3) NA NA
6–12 h 2.4 (0.8–6.8) NA NA
12 h 4.2 (1.5–12.1) NA NA
Treatment assignment
Enoxaparin 4.4 (1.7–11.2) NA NA
Unfractionated 2.7 (1.1–6.7) NA NA
Heparin
Early invasive NA 2.9 (1.4–6.1) NA
Early conservative NA 3.3 (1.6–6.7) NA
*Index diagnosis was determined by the local investigator. Patients with an index diagnosis other than unstable angina or
non–Q-wave MI are not included in these subgroup analyses.
CI  confidence interval; CK-MB  creatine kinase-MB subfraction; cTnI  cardiac troponin I; MI  myocardial
infarction. Other abbreviations as in Abbreviation box.
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each of these markers into the circulation may not result
from identical pathologic processes. Although the mecha-
nisms underlying our observations require further study, we
speculate below on several factors that may play a role.
In the present study, the extent of coronary atheroscle-
rosis was similar in patients with and without myoglobin
elevation. In contrast, patients with myoglobin elevation
were more likely to have an occluded coronary artery (TIMI
0 or 1 flow) and visible intracoronary thrombus and less
likely to have TIMI flow grade 3 than those without
myoglobin elevation. These observations remained signifi-
cant even in patients with cTnI elevation. Patients with
complete occlusion of an infarct artery are at higher risk for
mortality, but lower risk for reocclusion and recurrent MI,
than those with a patent infarct artery (22). Myoglobin
elevation may help to identify patients with infarct artery
occlusion who do not manifest ST elevation on the present-
ing ECG, such as those with complete thrombotic occlusion
of the circumflex artery. Due to the lower tissue-specificity
of myoglobin, the clinical cut-point is set relatively high;
thus, elevated levels of myoglobin may indicate larger areas
of infarction than detected by low-level elevations of tro-
ponins.
Myoglobin differs from cTnI in that it is smaller and
remains free in the cytoplasm of the cell, unbound to
contractile proteins (1). As a result, the kinetics for myo-
globin release differ from that for other cardiac proteins. In
experimental acute MI, myoglobin release is best described
by a one-compartment model: the amount of myoglobin
released into the circulation is equal to the amount of
myoglobin depleted from infarcted tissue (23). In contrast,
low-level troponin release may be more complex and occurs
frequently in patients with no detectable rise in other cardiac
biomarkers (20). The mechanism of “microinfarction” in
such patients is postulated to be embolization from complex
coronary plaque with obstruction of the coronary microcir-
culation (24). However, it remains possible that isolated
low-level troponin elevation is a manifestation of a patho-
logically distinct process, such as reversible myocyte injury
during reduced coronary blood flow. Such patients may be
at lower relative risk for death than patients with large
infarction but remain at increased risk for recurrent ischemic
events.
Finally, in some patients at risk for mortality, the source
of myoglobin elevation may be skeletal muscle rather than
the heart. Hypotension and reduced renal perfusion both
may result in skeletal muscle release of myoglobin (25) and
could contribute to mortality after ACS.
Study limitations. Time from symptom onset to random-
ization was not collected in the TACTICS-TIMI 18 trial.
In the TIMI 11B study, however, myoglobin elevation was
associated with a trend towards increased six-month mor-
tality in patients randomized 0 to 6 h, 6 to 12 h and 12 h
after symptom onset, and no interaction was found between
time to treatment, myoglobin elevation and six-month
mortality. Serial measurements of cardiac markers were not
performed, so the peak cardiac marker values cannot be
determined. It should be emphasized that the patients
evaluated in these studies may differ from the broader group
of patients who present to an emergency department with
chest discomfort. Entry into the TIMI 11B and
TACTICS-TIMI 18 studies required prior coronary dis-
ease, ST changes or cardiac marker elevation. Finally,
though commercially available and in common clinical use,
the assays in the present study were performed in a central
research laboratory rather than by local investigators. There-
fore, caution is warranted before generalizing findings from
the present study to clinical practice, where different assays
(with differing thresholds) may be used and where patients
may be at lower risk for mortality.
Conclusions. Myoglobin elevation identifies patients with
non–ST-elevation ACS who are at significantly increased
risk for six-month mortality, independent of baseline clin-
ical variables, ECG changes and elevation of other biomar-
kers such as cTnI and CK-MB. Although the mechanisms
underlying these observations are not known, we observed
that patients with myoglobin elevation have a greater
burden of intracoronary thrombus and are more likely to
present with an occluded coronary artery than those without
myoglobin elevation. In contrast with cTnI, myoglobin does
not discriminate the risk for nonfatal MI. These findings
suggest that different cardiac biomarkers may be predictive
of different cardiovascular end points and highlights the
need for future trials in which the relationship between
cardiac markers and individual cardiac end points is evalu-
ated.
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